Innovent Biologics : China Approves FUCASO NDA For Relapsed/Refractory Multiple Myeloma Treatment
3/7 03:54
(RTTNews) - Innovent Biologics Inc. and IASO Biotechnology said that China's National Medical Products Administration (NMPA) has approved the New Drug Application or NDA for FUCASO, the first fully-human BCMA-directed chimeric antigen receptor (CAR) T cell therapy for adult patie...